Scholar Rock Holding Corporation (SRRK)
Chart Events
Performance Outlook
| Previous Close | 50.60 |
| Open | 50.95 |
| Bid | 53.20 x 900 |
| Ask | 53.47 x 1200 |
| Day's Range | 48.06 - 54.01 |
| 52 Week Range | 9.53 - 66.72 |
| Volume | 183,258 |
| Avg. Volume | 238,278 |
| Market Cap | 1.801B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings Date | Mar 10, 2021 - Mar 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.25 |
Fair Value
Related Research
- Zacks
Analysts Estimate Scholar Rock Holding Corporation (SRRK) to Report a Decline in Earnings: What to Look Out for
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Scholar Rock Announces Senior Management Promotions
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President, Medical and Clinical Sciences, Head of Muscle Therapeutic Area.
- Business Wire
Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit.
